Transcenta Names Christopher Hwang Head Of Global Partnerships For Its HiCB Platform

Transcenta Therapeutics announced the appointment of Dr. Christopher Hwang as Head of Global Partnerships for its Highly Intensified Continuous Bioprocessing (HiCB) platform. In this role, Dr. Hwang will lead the company’s global technology out-licensing strategy, helping implement and expand the reach of Transcenta’s HiCB platform worldwide.

Dr. Hwang holds a PhD in Biochemical Engineering from the Massachusetts Institute of Technology and brings over 30 years of experience in biopharmaceutical CMC, technology development, and manufacturing. He has been instrumental in seven commercial and six mid- to late-stage projects involving recombinant proteins, monoclonal antibodies, and gene therapies, and previously held leadership positions at Genzyme and Sanofi. At Transcenta, he previously served as Chief Technology Officer and Executive Vice President of Process Development, playing a central role in building the HiCB platform. In his new position, he will focus on establishing global partnerships to drive adoption and value creation from this technology.

Dr. Hwang stated that the HiCB platform provides a scalable, practical solution to the rising costs and complexity of biologics manufacturing. He emphasized his commitment to collaborating with global partners to share expertise and explore innovative approaches to improve the efficiency, quality, and accessibility of therapies worldwide.

The HiCB platform integrates intensified continuous perfusion upstream processing with hybrid continuous downstream purification, enabling a 10–15 fold increase in productivity compared with conventional fed-batch processes. It maintains high product quality through shorter residence times and optimized culture conditions while reducing the cost of goods by at least 50%, lowering capital investment, and enabling agile, just-in-time production.

In late 2025, Dr. Hwang led Transcenta’s strategic collaboration and non-exclusive licensing agreement with EirGenix Inc.. Under this agreement, EirGenix gained a non-exclusive license to the HiCB platform, along with detailed process documentation, know-how, and regulatory support packages.

Building on this success, Transcenta is expanding its global partner network through additional non-exclusive licensing agreements. These partnerships help collaborators enhance manufacturing efficiency, reduce costs, and increase flexibility, while proceeds are reinvested to strengthen the HiCB platform and advance Transcenta’s R&D pipeline for next-generation therapeutics.